Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder

This new research suggests buprenorphine in CAM2038 formulation inhibits drug liking at low plasma concentrations, and suppresses the opioid cravings and withdrawal at even lower concentrations.

Buprenorphine is used to treat opioid use disorder. Weekly and monthly subcutaneous long-acting buprenorphine injections (CAM2038) provide more stable buprenorphine plasma levels and reduce the treatment burden, misuse, and diversion associated with sublingual transmucosal buprenorphine formulations.